Photocure ASA

Photocure ASA - New share capital registered

Oslo, Norway, 28 April 2020: Reference is made to the previous stock exchange

notices where Photocure ASA ("Photocure" or the "Company") announced the

allocation of 2,179,638 shares at a subscription price of NOK 65.50 per share,

raising gross proceeds of approximately NOK 143 million in a private placement

(the "Private Placement") .

The share capital increase pertaining to the issuance of the 2,179,638 new

shares has now been registered with the Norwegian Register of Business

Enterprises. The Company's new registered share capital is 11,988,012.50,

divided into 23,976,025 shares, each with a par value of NOK 0.50 per share.

Each share represents one vote in the Company's general meeting.

For further information, please contact:

Photocure ASA

Dan Schneider

President and CEO

Tel: + 1-609 759-6515

Erik Dahl

Chief Financial Officer

Tel: +47 450 55 000

About Photocure ASA

Photocure, The Bladder Cancer Company, delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, which makes

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo

Stock Exchange (OSE: PHO). The US headquarters for Photocure Inc., are in

Princeton, New Jersey. For more information, please visit us at

www.photocure.com, www.hexvix.com or www.cysview.com

This information is subject to the disclosure requirements pursuant to Section 5

-12 the Norwegian Securities Trading Act.

AI Terminal